These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 26461941)

  • 1. Compassionate and optimum use of new tuberculosis drugs.
    Matteelli A; D'Ambrosio L; Centis R; Tadolini M; Migliori GB
    Lancet Infect Dis; 2015 Oct; 15(10):1131-1132. PubMed ID: 26461941
    [No Abstract]   [Full Text] [Related]  

  • 2. Compassionate and optimum use of new tuberculosis drugs.
    Reed C; Mason L; Cox H; Seaworth B; Lessem E; Furin J
    Lancet Infect Dis; 2015 Oct; 15(10):1131. PubMed ID: 26461942
    [No Abstract]   [Full Text] [Related]  

  • 3. Bedaquiline plus delamanid for XDR tuberculosis.
    Lachâtre M; Rioux C; Le Dû D; Fréchet-Jachym M; Veziris N; Bouvet E; Yazdanpanah Y
    Lancet Infect Dis; 2016 Mar; 16(3):294. PubMed ID: 26973310
    [No Abstract]   [Full Text] [Related]  

  • 4. First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline.
    Tadolini M; Lingtsang RD; Tiberi S; Enwerem M; D'Ambrosio L; Sadutshang TD; Centis R; Migliori GB
    Eur Respir J; 2016 Sep; 48(3):935-8. PubMed ID: 27288039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Notes from the Field: Acquisition of Delamanid Under a Compassionate Use Program for Extensively Drug-Resistant Tuberculosis - United States, 2017.
    Lardizabal AA; Khan AN; Bamrah Morris S; Goswami ND
    MMWR Morb Mortal Wkly Rep; 2018 Sep; 67(35):996-997. PubMed ID: 30188880
    [No Abstract]   [Full Text] [Related]  

  • 6. Barriers to new drug development in respiratory disease.
    Brigden G; du Cros P; Wong S
    Eur Respir J; 2016 Jan; 47(1):356-7. PubMed ID: 26721975
    [No Abstract]   [Full Text] [Related]  

  • 7. Emergence of Low-level Delamanid and Bedaquiline Resistance During Extremely Drug-resistant Tuberculosis Treatment.
    Polsfuss S; Hofmann-Thiel S; Merker M; Krieger D; Niemann S; Rüssmann H; Schönfeld N; Hoffmann H; Kranzer K
    Clin Infect Dis; 2019 Sep; 69(7):1229-1231. PubMed ID: 30933266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. India plans to expand access to new tuberculosis drug.
    Sharma DC
    Lancet; 2017 Feb; 389(10070):685. PubMed ID: 28229866
    [No Abstract]   [Full Text] [Related]  

  • 9. [New antitubercular agents are not where where we need them to be].
    Nau JY
    Rev Med Suisse; 2015 Dec; 11(499):2408-9. PubMed ID: 26852561
    [No Abstract]   [Full Text] [Related]  

  • 10. Cost-effectiveness of incorporating bedaquiline into a treatment regimen for MDR/XDR-TB in Germany.
    Wolfson LJ; Gibbert J; Wirth D; Diel R
    Eur Respir J; 2015 Dec; 46(6):1826-9. PubMed ID: 26493796
    [No Abstract]   [Full Text] [Related]  

  • 11. Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant Tuberculosis.
    Maryandyshev A; Pontali E; Tiberi S; Akkerman O; Ganatra S; Sadutshang TD; Alffenaar JW; Amale R; Mullerpattan J; Topgyal S; Udwadia ZF; Centis R; D'Ambrosio L; Sotgiu G; Migliori GB
    Emerg Infect Dis; 2017 Oct; 23(10):1718-21. PubMed ID: 28758888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Timing is everything for compassionate use of delamanid.
    Barry CE
    Nat Med; 2015 Mar; 21(3):211. PubMed ID: 25742452
    [No Abstract]   [Full Text] [Related]  

  • 13. Bedaquiline and Delamanid in Children With XDR Tuberculosis: What is prolonged QTc?
    Shah I; Gandhi S; Shetty NS
    Pediatr Infect Dis J; 2020 Jun; 39(6):512-513. PubMed ID: 32032176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Access sought to tuberculosis drug from nutraceutical company.
    Gruber K
    Nat Med; 2015 Feb; 21(2):103. PubMed ID: 25642939
    [No Abstract]   [Full Text] [Related]  

  • 15. Compassionate use of delamanid in combination with bedaquiline for the treatment of multidrug-resistant tuberculosis.
    Hafkin J; Hittel N; Martin A; Gupta R
    Eur Respir J; 2019 Jan; 53(1):. PubMed ID: 30361253
    [No Abstract]   [Full Text] [Related]  

  • 16. Bedaquiline or delamanid for rifampin-resistant tuberculosis?
    Lessem E; Cox V; Furin J
    Lancet Respir Med; 2017 Oct; 5(10):772-774. PubMed ID: 28887015
    [No Abstract]   [Full Text] [Related]  

  • 17. Delamanid for Extensively Drug-Resistant Tuberculosis.
    Gupta R; Geiter LJ; Wells CD; Gao M; Cirule A; Xiao H
    N Engl J Med; 2015 Jul; 373(3):291-2. PubMed ID: 26176402
    [No Abstract]   [Full Text] [Related]  

  • 18. Drug-resistance mechanisms and tuberculosis drugs.
    Köser CU; Javid B; Liddell K; Ellington MJ; Feuerriegel S; Niemann S; Brown NM; Burman WJ; Abubakar I; Ismail NA; Moore D; Peacock SJ; Török ME
    Lancet; 2015 Jan; 385(9965):305-7. PubMed ID: 25706840
    [No Abstract]   [Full Text] [Related]  

  • 19. Combined treatment of drug-resistant tuberculosis with bedaquiline and delamanid: a systematic review.
    Pontali E; Sotgiu G; Tiberi S; Tadolini M; Visca D; D'Ambrosio L; Centis R; Spanevello A; Migliori GB
    Eur Respir J; 2018 Jul; 52(1):. PubMed ID: 29903862
    [No Abstract]   [Full Text] [Related]  

  • 20. Bedaquiline and delamanid in combination for treatment of drug-resistant tuberculosis.
    Mohr E; Ferlazzo G; Hewison C; De Azevedo V; Isaakidis P
    Lancet Infect Dis; 2019 May; 19(5):470. PubMed ID: 31034392
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.